Tango Therapeutics TNGX TNG961Direct Program Expenses-RD — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's tng961direct program expenses-rd — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's tng961direct program expenses-rd — research and development expense?
- Tango Therapeutics (TNGX) reported tng961direct program expenses-rd — research and development expense of $408K in Q1 2026.
- How has Tango Therapeutics's tng961direct program expenses-rd — research and development expense changed year-over-year?
- Tango Therapeutics's tng961direct program expenses-rd — research and development expense decreased by 81.6% year-over-year, from $2.22M to $408K.
- What does tng961direct program expenses-rd — research and development expense mean?
- This metric represents the direct research and development expenditures specifically allocated to the TNG961 clinical or preclinical program. It captures the costs associated with advancing this specific therapeutic candidate through the drug development pipeline, including laboratory research, clinical trial activities, and regulatory preparation. Tracking these costs allows investors to evaluate the capital intensity and progress of individual pipeline assets within the company's broader oncology portfolio.